| Literature DB >> 36212427 |
Sven Voigtländer1, Amir Hakimhashemi1, Nina Grundmann1, Franziska Rees1, Martin Meyer1, Hana Algül2, Jacqueline Müller-Nordhorn1.
Abstract
Background: Recent studies reported an increase in colorectal cancer incidence for adults below 50 years. There is a lack of studies distinguishing between histological subgroups, especially from Europe.Entities:
Keywords: adenocarcinoma; appendiceal malignancies; colorectal cancer; epidemiology; histology; incidence; neuroendocrine neoplasm
Year: 2022 PMID: 36212427 PMCID: PMC9533724 DOI: 10.3389/fonc.2022.904546
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 5.738
Characteristics of colorectal cancer cases in Bavaria from 2005 to 2019.
| Characteristic | Number (percentage) |
|---|---|
| Total cases | 139,420 (100.0) |
|
| |
| 20–29 years | 517 (0.4) |
|
| |
| Male | 78,872 (56.6) |
|
| |
| Colon (without appendix) | 89,176 (64.0) |
|
| |
| Adenocarcinomas | 109,825 (78.8) |
|
| |
| I | 23,801 (17.1) |
Figure 1Annual age-standardized incidence rates per 100,000 persons for the age group 20–29 years by anatomic site and histological subgroup in Bavaria, 2005–2019. Error bars show 95% confidence intervals.
Figure 4Annual age-standardized incidence rates per 100,000 persons for the age group 50 years and above by anatomic site and histological subgroup in Bavaria, 2005–2019. Error bars show 95% confidence intervals.
Three-year average annual age-standardized incidence rates for colorectal cancer cases in 2005–2007 and 2017–2019 by anatomic site, histological subgroup, and age in Bavaria.
| ASIR per 100,000 persons | ||||
|---|---|---|---|---|
| 2005–2007 | 2017–2019 | Absolute change | Relative change (in %) | |
|
| ||||
| Adenocarcinomas | ||||
| 20–29 years | 0.78 | 0.90 | 0.12 | +15% |
| 30–39 years | 3.79 | 4.51 | 0.72 | +19% |
| 40–49 years | 16.50 | 16.09 | −0.41 | −2% |
| 50 years and above | 132.55 | 105.95 | −26.60 | −20%* |
| Neuroendocrine neoplasms | ||||
| 20–29 years | 0.52 | 1.38 | 0.86 | +165%* |
| 30–39 years | 0.47 | 1.53 | 1.07 | +226%* |
| 40–49 years | 0.80 | 1.82 | 1.03 | +128%* |
| 50 years and above | 1.78 | 2.72 | 0.94 | +53%* |
|
| ||||
| Adenocarcinomas | ||||
| 20–29 years | 0.49 | 0.60 | 0.11 | +22% |
| 30–39 years | 2.28 | 2.54 | 0.26 | +12% |
| 40–49 years | 8.92 | 8.37 | −0.56 | −6% |
| 50 years and above | 81.52 | 68.26 | −13.27 | −16%* |
| Neuroendocrine neoplasms | ||||
| 20–29 years | 0.04 | 0.02 | −0.03 | −57% |
| 30–39 years | 0.07 | 0.12 | 0.05 | +81% |
| 40–49 years | 0.15 | 0.15 | 0.00 | +0% |
| 50 years and above | 0.58 | 0.78 | 0.20 | +34% |
|
| ||||
| Adenocarcinomas | ||||
| 20–29 years | 0.09 | 0.04 | −0.05 | −58% |
| 30–39 years | 0.17 | 0.20 | 0.03 | +15% |
| 40–49 years | 0.22 | 0.58 | 0.36 | +164%* |
| 50 years and above | 0.69 | 1.26 | 0.57 | +83%* |
| Neuroendocrine neoplasms | ||||
| 20–29 years | 0.41 | 1.16 | 0.75 | +184%* |
| 30–39 years | 0.27 | 0.88 | 0.61 | +226%* |
| 40–49 years | 0.31 | 0.89 | 0.59 | +192%* |
| 50 years and above | 0.44 | 0.54 | 0.10 | +23% |
|
| ||||
| Adenocarcinomas | ||||
| 20–29 years | 0.20 | 0.25 | 0.05 | +26% |
| 30–39 years | 1.34 | 1.77 | 0.43 | +32% |
| 40–49 years | 7.35 | 7.14 | −0.21 | −3% |
| 50 years and above | 50.34 | 36.44 | −13.90 | −28%* |
| Neuroendocrine neoplasms | ||||
| 20–29 years | 0.07 | 0.20 | 0.13 | +193% |
| 30–39 years | 0.13 | 0.53 | 0.40 | +309%* |
| 40–49 years | 0.35 | 0.78 | 0.43 | +126%* |
| 50 years and above | 0.76 | 1.40 | 0.64 | +84%* |
ASIR, average annual age-standardized incidence rate per 100,000 persons.
*Indicates that the relative change is significantly different from zero with a significance level of 5%.
Average annual percentage change in age-standardized incidence rates for colorectal cancer cases from 2005 to 2019 by anatomic site, histological subgroup, and age in Bavaria.
| AAPC (in %) | 95% CI (in %) | |
|---|---|---|
|
| ||
| Adenocarcinomas | ||
| 20–29 years | 1.5 | −2.6 to 5.8 |
| 30–39 years | 1.8* | 0.4 to 3.2 |
| 40–49 years | −0.2 | −1.0 to 0.6 |
| 50 years and above | −2.0* | −2.3 to −1.7 |
| Neuroendocrine neoplasms | ||
| 20–29 years | 10.5* | 4.0 to 17.4 |
| 30–39 years | 10.1* | 5.3 to 15.1 |
| 40–49 years | 7.7* | 5.1 to 10.3 |
| 50 years and above | 3.9* | 2.5 to 5.3 |
|
| ||
| Adenocarcinomas | ||
| 20–29 years | 2.3 | −1.4 to 6.2 |
| 30–39 years | 1.0 | −1.6 to 3.6 |
| 40–49 years | −0.3 | −1.4 to 0.7 |
| 50 years and above | −1.7* | −2.1 to −1.3 |
| Neuroendocrine neoplasms | ||
| 20–29 years | 0.0± | |
| 30–39 years | 0.0± | |
| 40–49 years | 3.8 | −4.2 to 12.6 |
| 50 years and above | 2.0 | −0.6 to 4.6 |
|
| ||
| Adenocarcinomas | ||
| 20–29 years | 0.0± | |
| 30–39 years | 4.0 | −3.0 to 11.6 |
| 40–49 years | 8.8* | 3.1 to 14.9 |
| 50 years and above | 5.0* | 2.6 to 7.4 |
| Neuroendocrine neoplasms | ||
| 20–29 years | 10.5* | 4.0 to 17.4 |
| 30–39 years | 10.5* | 3.2 to 18.4 |
| 40–49 years | 11.7* | 4.3 to 19.7 |
| 50 years and above | 3.1 | −1.1 to 7.5 |
|
| ||
| Adenocarcinomas | ||
| 20–29 years | 0.0± | |
| 30–39 years | 3.0* | 1.2 to 4.8 |
| 40–49 years | −0.6 | −1.7 to 0.6 |
| 50 years and above | −2.8* | −3.0 to −2.5 |
| Neuroendocrine neoplasms | ||
| 20–29 years | 0.0± | |
| 30–39 years | 11.1* | 6.0 to 16.5 |
| 40–49 years | 7.3* | 3.1 to 11.8 |
| 50 years and above | 6.3* | 4.0 to 8.6 |
AAPC, average annual percentage change; CI, confidence interval.
*Indicates that AAPC is significantly different from zero with a significance level of 5%.
±No AAPC estimate due to years with zero cases.
Figure 5Annual age-standardized mortality rates per 100,000 persons for colorectal cancer cases by age in Bavaria, 2005–2019. Scale of the y-axis varies. Error bars show 95% confidence intervals.